Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Guideline discrepancies may influence HFrEF and HFpEF decisions; leaves open the need for harmonized evidence on ARBs, devices, and aldosterone antagonists.
The European Society of Cardiology (ESC) first published guidelines on the diagnosis of heart failure in 1995, followed two years later by guidelines on treatment. A combined guidelines version was published by the ESC in 2001 and updated in 2005.18 A further guideline update is currently in preparation, with publication due in 2008. There are three North American guidelines, which differ from the ESC guidelines in terms of process of development, content and implementation. The American College of Cardiology/ American Heart Association (ACC/AHA) guidelines were the first North American guidelines to be published, with the initial version in 1995 and a second six years later. The latest version is dated 2005.11 The two other North American guidelines considered in this review have been published by the Heart Failure Society of America and the Canadian Cardiovascular Society. Both these sets of guidelines were produced first in 1999 with an update in 2006.1,9 Guidelines from the ACC/AHA, HFSA, and ESC are all produced in a similar manner, driven by a small writing committee. The ESC guidelines on heart failure, for example, have a writing committee consisting of eight core members and 11 others, including a nurse, echocardiographer, specialist electrophysiologist, and two internists. The ESC guidelines are submitted in draft form to a complex review process involving external reviewers before the finalized guidelines are released to the 49 member countries of the ESC. The ESC, ACC/AHA, and HFSA guidelines are each produced in a full text version while these and the CCS guidelines are also produced in a short version with lengths ranging from 23–30 pages. All four sets of guidelines are disseminated similarly, in both print and online versions; the latter are available for download at the society websites. Electronic versions of the guidelines are increasingly popular with healthcare professionals, and, within the ESC, the heart failure guidelines are among the most frequently downloaded of all guidelines. Slide kits, pocket guideline, and personal digital assistant versions are also prepared. The ESC, in particular, also actively organizes a number of dedicated educational guideline sessions at its annual congresses as well as special sessions at the national society level. The pharmaceutical industry plays an important role as a vector for dissemination of guidelines in both North America and Europe. The ESC, HFSA, and CCS guidelines discuss treatments within the context of functional limitations, measured by New York Heart Association (NYHA) Class I to IV. By contrast, the ACC/AHA guidelines utilize a four-stage classification of heart failure which differs substantially from the functional NYHA classification: Stage A: High risk for developing heart failure Stage B: Asymptomatic heart failure Stage C: Past or current symptoms of heart failure Stage D: End-stage heart failure Level A: Data derived from multiple randomized controlled trials (RCTs) or meta-analyses Level B: Data derived from a single RCT or large non-randomized studies Level C: Consensus of experts / small studies / retrospective studies / registries Class I: Treatment is beneficial Class II: Conflicting / diverging opinion about usefulness of evidence and efficacy ○ IIa. Favors usefulness / efficacy ○ IIb. Usefulness / efficacy less well established Class III: Treatment not useful / effective or may be harmful Is recommended Should be considered May be considered Further discussion of the similarities and differences between the four guidelines described here is reviewed by.14 ACE inhibitors are recommended in all four guidelines for patients with chronic heart failure with left ventricular systolic dysfunction, with a Level A, Class I recommendation. This strong recommendation is reassuring and appropriate given the large number of studies showing the benefits of ACE inhibitors in this setting. The ESC and CCS guidelines further recommend particular drugs within the ACE inhibitor class. All four guidelines also recommend beta-blockers with a Level A, Class I recommendation for patients with chronic heart failure with left ventricular systolic dysfunction. All guidelines, with the exception of those from the HFSA, specify particular beta-blockers – namely, bisoprolol, carvedilol, and metoprolol succinate CR/XL. The ESC additionally recommends nebivolol, based on the SENIORS trial.6 There are some discrepancies between the guidelines in their recommendations on the use of aldosterone antagonists. Whereas the ESC, ACC/AHA, and CCS guidelines provide a Level B, Class I recommendation, the HFSA offers a Level A, Class I recommendation. The HFSA recommendation may be considered surprising, as only one study has shown benefit for an aldosterone antagonist (i.e. spironolactone) in chronic heart failure – namely, RALES.16 A second large trial, EPHESUS, demonstrated benefit, but investigated only patients after myocardial infarction.17 For angiotensin receptor blockers, the guidelines recommendations are more complicated. The simplest case is for patients intolerant to ACE inhibitors. The three North American guidelines provide a Level A, Class I recommendation, whereas the ESC gives only a Level B, Class I recommendation in this indication. Strictly speaking, there has been only one trial that showed benefit for an angiotensin receptor blocker in chronic heart failure (CHARM-Alternative)8 and the ESC guidelines may be considered more consistent with the available evidence. It may be that the North American guidelines took into consideration a retrospective analysis of patients untreated by ACE inhibitor in Val-HeFT.13 Greater divergence between the guidelines in the use of angiotensin receptor blockers is shown for those patients who remain symptomatic on ACE inhibitors and beta-blockers. The ESC, alone among the guidelines, makes recommendations based on practical outcomes. For mortality in this situation, the ESC gives a Level B, Class IIb recommendation, based on one trial that showed benefit (CHARM-Added),15 but another that did not (Val-HeFT).13 For worsening heart failure, the ESC provides a Level A, Class I recommendation based on two positive trials. The CCS provides a strong (Level A, Class I) recommendation for the addition of angiotensin receptor blockers, which appears to relate to hospitalization. The ACC/AHA guidelines give a Level B recommendation (in line with the ESC) but a surprisingly low Class IIb recommendation. The HFSA provides a Level A recommendation, indicating inclusion of both Val-HeFT and CHARM in their consideration, but a Class IIa recommendation. These differences across the guidelines in their recommendations to use angiotensin receptor blockers in combination have potential to cause confusion – particularly in the USA, where the two national guidelines do not convey the same message. Another confusing difference between the US guidelines relates to the side effects associated with angiotensin receptor blockers. The HFSA suggests that angiotensin receptor blockers should be considered in patients who develop angioedema while on an ACE inhibitor, with recognition that angioedema has been reported infrequently with these agents. The ACC/AHA, by contrast, states that although angiotensin receptor blockers may be considered as an alternative therapy for patients with angioedema while on an ACE, extreme caution is advised in this setting. For patients in sinus rhythm, the ESC and HFSA guidelines provide a Level A, Class IIa recommendation. A Level A recommendation is provided because these guidelines took into consideration the DIG trial and meta-analyses;5,10 the Class IIa recommendation derives from the fact that the DIG and other trials are older studies performed before the era of ACE inhibitors and, more importantly, beta-blockers. Perhaps surprisingly, the CCS guidelines provide a Level A, Class I recommendation. Finally, the ACC/AHA guidelines provide a recommendation at Level B, which indicates that only DIG was considered, and Class IIa, which probably takes into account the historical context of this older trial. It is notable that the ACC/AHA guidelines provide a more favorable Class recommendation for digoxin than for angiotensin receptor blockers, which appears to suggest an inconsistency in approach. The ESC guidelines are the only guidelines to make a distinction between symptoms and heart failure hospitalization and mortality in their recommendations for cardiac resynchronization therapy (CRT). The ESC provides a Level A, Class I recommendation for use of CRT for symptoms and hospitalization based on CARE-HF and COMPANION.3,4 For mortality, the ESC provides a Level B, Class I recommendation, because only CARE-HF has to date demonstrated benefit. The three North American guidelines offer some variation in recommendations for CRT. The ACC/AHA and CCS provide a Level A, Class I recommendation, whereas the HFSA gives a lower Class recommendation (IIa). The ESC and HFSA guidelines make no distinction between ischaemic and non-ischaemic etiologies in their recommendations for implantable cardioverter-defibrillator (ICD) use. The ESC gives a Level A, Class I recommendation for ICDs, compared to a Level A, Class IIa recommendation from the HFSA. The ACC/AHA and CCS guidelines do make a distinction between ischaemic and non-ischaemic etiologies, probably because their interpretation of the evidence for ischaemic heart failure is based on both SCD-HeFT2 and a number of post-myocardial infarction trials. This indication is given a Level A, Class I recommendation. By contrast, there are only subgroup analyses from SCD-HeFT and the inconclusive results of the DEFINITE trial12 on which to base recommendations in non-ischaemic cardiomyopathy, which explains the Level B recommendations in both the ACC/AHA and CCS guidelines. The threshold of ejection fraction (EF) also varies between the guidelines. The ACC/AHA recommends an EF of <30%, while the other guidelines consider a range of EFs between 30–35%. The CCS gives a lower grade of recommendation for higher EFs. The ESC guidelines recommend that attempts should be made to identify the cause as well as to identify and correct precipitating factors for heart failure with preserved systolic function (PSF). The ESC guidelines insist in particular on control of heart rate and suppression of tachyarrhythmias. For the pharmacological treatment of HF with PSF, the ESC guidelines recommendations are largely speculative due to a scarcity of data. Medications that are recommended (Class IIa, Level C) are ACE inhibitors, diuretics, beta-blockers, verapamil-type calcium antagonists, and angiotensin receptor blockers. The ESC guidelines conclude that: “In general, the treatment of LVEF/diastolic dysfunction remains difficult and unsatisfactory.” The ACC/AHA guidelines provide a low level (Level IIb, Class C) recommendation for the restoration/maintenance of sinus rhythm in patients with atrial fibrillation and normal LVEF. The same recommendation (Level IIb, Class C) applies to all pharmacological agents, including digitalis, in patients with heart failure and normal LVEF. It is noteworthy that the ESC guidelines do not offer a recommendation on digitalis. A recent paper based on a subgroup analysis of patients with PSF in the DIG trial indicated that digitalis offers no real benefit. The HFSA provides a surprisingly strong level of recommendation for HF with PSF, including Level I for aggressive blood pressure monitoring, low sodium diet, diuretic treatment, and beta-blockers, and Level IIa for angiotensin receptor blockers and ACE inhibitors. The class, however, is C throughout, with the exception of angiotensin receptor blockers (Class B). The heterogeneity among the guidelines in terms of recommendations for HF with PSF is a clear reflection of the scarcity of data in this setting. While writing guidelines is a valuable exercise, the implementation of the guidelines in practice is equally important. Two indicators of performance in the management of patients with chronic heart failure and depressed ejection fraction are rates of prescriptions of ACE inhibitors at discharge, and rates of ejection fraction measurement. US data from the ADHERE registry7 (Figure 1) show that approximately three quarters of patients were prescribed an ACE inhibitor at discharge and >80% had an EF determination. The situation in Europe appears to be similar, where 80% of patients received an EF measurement in the European Heart Failure Survey (EHFS) II, compared to 58% in the earlier EHFS I. A comparison of prescriptions between EHFS II and EHFS I also provides reassurance that physicians are taking the ESC guidelines into consideration. Rates of prescriptions for ACE inhibitors, beta-blockers, and aldosterone antagonists during hospitalization all showed an increase between the two surveys (Figure 2). The same applies to prescriptions of outpatients. There are discrepancies between the ESC, ACC/AHA, HFSA, and CCS guidelines in their recommended procedures and treatments in chronic heart failure. These discrepancies reflect in part the subjectivity involved in interpreting the evidence available. Some discrepancies also probably relate to the fact that some guideline committees considered disease-related trials and others use specific outcomes on which to base their recommendations. The weight to be given to meta-analyses in recommendations was probably also considered differently by the four committees. It is helpful that in Europe the majority of national cardiovascular societies have endorsed the ESC guidelines, with debate largely limited to those areas where the evidence base is small or developing.
No takes yet. Share an insight, caveat, or question.
Michel Komajda (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: